Changes/additions to materials:

29th March 2010: NICE has reissued its guideline on cardiovascular risk assessment and lipid modification (CG67) removing the recommendation to use a specific method for risk estimation (based on the Framingham equation).  NICE considered new evidence relating to QRISK but concluded that it was not able to recommend one cardiovascular risk estimation method over another. It has therefore left the decision to the NHS locally to use the method best suited to their requirements. All other recommendations in the guideline are unchanged. 

NICE guidance on CV risk assessment published
Since these materials were prepared, NICE has published guidance on CV risk assessment and lipid modification. The materials on this floor of NPCi are currently being updated and will be available shortly. In the meantime, key issues relating to the NICE recommendations are discussed in a blog and further information is available on the lipids floor of NPCi

We have not prepared a patient decision aid about cardiovascular risk assessment.

However, you may be interested in the decision aids on other floors of NPCi which deal with:

• Use of statins (lipids floor)
• Smoking cessation (CV lifestyle floor)
• Blood pressure control (hypertension floor)
• Blood pressure or blood glucose control (type 2 diabetes floor)

If you are interested in finding out more about how to make the best use of patient decision aids, the following may be of interest:

• Making use of patient decision aids
• Cochrane decision aid registry
• Using decision aids in practice

Let us know what you think about our PDAs and how you use them

We are always grateful for feedback, indeed without it most of this work would not have been possible. We should be very grateful if you would take about 5 minutes to complete a short anonymous survey on your experiences with these PDAs. Click here to take the survey.